IN THE SPECIFICATION:

On page 6, following the heading BRIEF DESCRIPTION OF THE DRAWINGS, please delete lines 2 through 12 and replace them with the following. A copy showing the additions and deletions is attached hereto.

--Figures 1 A-B. Nucleotide sequence of the murine *TRP8* cDNA encoding murine TRP8, SEQ ID NO: 1.

--Figure 2. Deduced amino acid sequence of the murine TRP8 transient receptor potential channel, SEQ ID NO: 2.--

--Figures 3A-B. Nucleotide sequence of the human *TRP8* cDNA encoding human TRP8, SEQ ID NO: 3.

A1 --Figure 4. Deduced amino acid sequence of the human TRP8 protein transient receptor potential channel, SEQ ID NO: 4--.

--Figure 5. Amino acid sequence of the murine TRP8 (upper lines); versus human TRP8 (lower lines), as represented in part by SEQ ID NO: 2 and SEQ ID NO: 4, respectively, and displayed in SEQ ID NO: 6. Each pair of lines corresponds to a predicted mouse/human exon.--

Please delete the last full paragraph on page 10, starting on line 17, through line 19, and replace it with the following paragraph:

A2 -- The cDNA sequence and deduced amino acid sequence of murine TRP8 are shown in Figures 1 (SEQ ID NO: 1) and 2 (SEQ ID NO: 2), respectively. The cDNA and deduced amino acid sequence of human TRP8 are shown in Figures 3 (SEQ ID NO: 3) and 4 (SEQ ID NO: 4), respectively.--

Please delete the paragraph starting at line 20, on page 10 and bridging page 11, and replace it with the following paragraph:

A3 --The *TRP8* nucleotide sequences of the invention include: (a) the DNA sequences shown in FIG. 1 (SEQ ID NO: 1) or 3 (SEQ ID NO: 3) or contained in the cDNA clone pMR24 within E. coli strain XL10 Gold as deposited with the American Type Culture Collection (ATCC Accession No.); (b) nucleotide

sequences that encode the amino acid sequence shown in Figure 2 (SEQ ID NO: 2)or 4 (SEQ ID NO: 4) or the TRP8 amino acid sequence encoded by the cDNA clone pMR24 as deposited with the ATCC; (c) any nucleotide sequence that (i) hybridizes to the nucleotide sequence set forth in (a) or (b) under stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M $NaHPO_4$, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65EC, and washing in 0.1xSSC/0.1% SDS at 68EC (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and (ii) encodes a functionally equivalent gene product; and (d) any nucleotide sequence that hybridizes to a DNA sequence that encodes the amino acid sequence shown in Figure 1 (SEQ ID NO: 1) or 3 (SEQ ID NO: 3), or that is contained in cDNA clone pMR24 as deposited with the ATCC, under less stringent conditions, such as moderately stringent conditions, e.g., washing in 0.2xSSC/0.1% SDS at 42EC (Ausubel et al., 1989 supra), yet which still encodes a functionally equivalent TRP8 gene product. Functional equivalents of the TRP8 protein include naturally occurring TRP8 present in species other than mice and humans. The invention also includes degenerate variants of sequences (a) through (d). The invention also includes nucleic acid molecules, that may encode or act as *TRP8* antisense molecules, useful, for example, in *TRP8* gene regulation (for and/or as antisense primers in amplification reactions of *TRP8* gene nucleic acid sequences).

R3

Please delete the paragraph starting at line 21, on page 13, bridging page 14, and replace it with the following paragraph:

--Figures 2 (SEQ ID NO: 2) and 4 (SEQ ID NO: 4) show the deduced amino acid sequence of the murine and human TRP8 protein, respectively. The TRP8 amino acid sequences of the invention include the amino acid sequence shown in Figure 2 (SEQ ID NO: 2) or Figure 4 (SEQ ID NO: 4), or the amino acid sequence encoded by cDNA clone pMR24 as deposited with the ATCC. Further, TRP8s of other species are encompassed by the invention. In fact, any TRP8 protein encoded by the *TRP8* nucleotide sequences described in Section 5.1, above, is within the scope of the invention.--

R4

Please delete the paragraph starting at line 15, on page 38, bridging page 39, and replace it with the following paragraph: